The present invention provides a combination of (a) an antipsychotic and (b) an alpha4/beta2 (.alpha.4.beta.2)-neuronal nicotinic receptor agonist. The invention further relates to pharmaceutical compositions comprising said combination and to the use of the combination in therapy. The invention further relates to a kit comprising the combination and use of said kit in therapy.